Healthcare Funding Bill Signals Major Policy Shift: PBM Reform and Telehealth Extension Analysis

By Elena Pak, Credentialing Department, WCH

The recent signing of federal funding legislation by President Donald Trump represents far more than a simple continuation of government operations. This legislative package, which ended a brief partial government shutdown, introduces significant structural changes to the American healthcare landscape through pharmacy benefit manager reforms, extended telehealth provisions, and hospital-at-home program continuity. These measures collectively signal a fundamental realignment in how healthcare services are regulated, delivered, and reimbursed across the United States.

The Political Context: From Shutdown to Sweeping Reform

The legislation emerged from a tense political standoff that began when Congress failed to pass appropriations before the January 31 deadline, triggering a partial government shutdown that affected the Department of Health and Human Services among other agencies. The impasse was resolved through a Senate-brokered deal that funded most federal operations through September 30, though notably excluded the Department of Homeland Security amid controversies surrounding immigration enforcement actions.

The House approved the measure with a narrow 217-214 vote, reflecting deep partisan divisions even as both parties recognized the necessity of resolving the funding crisis. What makes this legislative package particularly significant is that lawmakers seized the opportunity not merely to restore funding, but to attach substantive healthcare policy reforms that had been debated for years without resolution.

PBM Reform: Attacking the Middleman Problem

Perhaps the most consequential element of the legislation addresses pharmacy benefit managers, the controversial intermediaries between drug manufacturers, insurers, and pharmacies. The new law mandates transparency requirements for PBMs and prohibits them from linking their compensation to drug manufacturers’ list prices in Medicare Part D.

This reform targets a fundamental conflict of interest in pharmaceutical pricing. PBMs have historically operated with minimal oversight, often negotiating rebates from drug manufacturers based on list prices while simultaneously determining which medications appear on insurance formularies. Critics argue this system incentivizes PBMs to favor higher-priced drugs with larger rebates rather than lower-cost alternatives that might better serve patients.

The prohibition on linking PBM compensation to list prices represents an attempt to eliminate this perverse incentive structure. By decoupling PBM revenue from drug prices, legislators hope to reduce the financial motivation for maintaining high list prices throughout the pharmaceutical supply chain. This could theoretically create downward pressure on drug costs, though the actual impact remains uncertain.

Industry reaction has been predictably polarized. Pharmacy groups, including the Senior Care Pharmacy Coalition, celebrated the reforms as advancing transparency and fairness in prescription drug markets. Coalition president Alan Rosenbloom characterized the legislation as a significant step toward greater accountability in pharmaceutical pricing.

However, the Pharmaceutical Care Management Association, the primary PBM lobbying organization, dismissed the reforms as ineffective political theater. PCMA’s chief communications officer Brendan Buck suggested that PBMs have become scapegoats for dysfunction created by pharmaceutical manufacturers themselves, arguing that the new oversight should now turn toward drugmakers rather than middlemen. This defense highlights the complexity of pharmaceutical pricing, where multiple actors share responsibility for escalating costs.

The skepticism from PBM advocates contains some validity. While the reforms address one aspect of a broken system, they do not fundamentally restructure pharmaceutical markets. Drug manufacturers retain pricing power, insurance companies continue consolidating market share, and PBMs may find alternative compensation mechanisms that preserve their profitability while technically complying with new restrictions.

Telehealth: From Temporary Flexibility to Structural Integration

The legislation extends pandemic-era telehealth flexibilities in Medicare through 2027, a decision with profound implications for healthcare delivery models. Since March 2020, Medicare beneficiaries have enjoyed expanded access to remote medical services, including visits conducted from home rather than originating from specific healthcare facilities. These provisions were initially justified as emergency measures but have proven sufficiently valuable that their elimination became politically untenable.

The two-year extension provides healthcare organizations with unprecedented planning certainty. Previous extensions had been measured in months, creating perpetual uncertainty that discouraged long-term investment in telehealth infrastructure and staffing. Organizations found themselves caught in cycles of expansion and contraction, unable to commit resources when the regulatory foundation might disappear within weeks.

The 2027 horizon fundamentally changes this dynamic. Healthcare systems can now develop comprehensive telehealth strategies with reasonable confidence in reimbursement continuity. This enables investments in specialized equipment, training programs, and workflow redesign that would be financially impractical under short-term authorizations.

Moreover, the extended timeline facilitates crucial data collection and program evaluation. Healthcare researchers and policymakers will have several years to assess telehealth outcomes, patient satisfaction, cost-effectiveness, and quality metrics. This evidence base will inform future decisions about whether to make telehealth flexibilities permanent, modify their scope, or allow them to sunset.

The policy shift also reflects changing public expectations. During the pandemic, millions of Americans experienced telehealth services for the first time and discovered benefits including reduced travel burdens, faster access to specialists, and greater scheduling flexibility. Any attempt to eliminate these options would face significant political backlash, particularly from elderly and rural populations who face the greatest barriers to in-person care.

Hospital-at-Home: Reimagining Acute Care Delivery

The extension of the Acute Hospital Care at Home Program through September 2030 represents perhaps the most forward-looking element of the legislation. This initiative, which allows approved hospitals to deliver inpatient-level care in patients’ residences, challenges fundamental assumptions about where acute medical treatment must occur.

The five-year extension addresses a critical obstacle that had plagued the program since its inception. Under previous short-term authorizations, hospitals faced enormous uncertainty when deciding whether to invest in hospital-at-home capabilities. Building these programs requires substantial upfront costs including staff training, equipment procurement, logistics systems, and clinical protocol development. Without assurance that Medicare reimbursement would continue, many institutions hesitated to commit resources.

The 2030 deadline transforms this calculation. Healthcare systems can now develop comprehensive business plans, hire specialized staff, establish vendor relationships, and refine operational processes with confidence that their investments will have time to generate returns. This stability should accelerate program adoption and allow for sophisticated quality improvement initiatives.

Krista Drobac, executive director of Moving Health Home, emphasized this dynamic in her response to the legislation, noting that the long-term extension enables providers to plan, invest, and scale programs in ways that benefit patients and communities. Critically, she highlighted the opportunity for large-scale data collection that could definitively demonstrate the program’s value and convince lawmakers to make it permanent.

Hospital-at-home programs offer potential advantages across multiple dimensions. For patients, receiving acute care in familiar surroundings can reduce stress, improve sleep quality, and facilitate family involvement in care decisions. For healthcare systems, these programs can alleviate capacity constraints in physical facilities, potentially reduce facility costs, and improve patient satisfaction scores. For payers, hospital-at-home may deliver comparable outcomes at lower cost than traditional inpatient care.

However, significant challenges remain. Not all patients are appropriate candidates for home-based acute care, and careful selection criteria are essential to ensure safety. Infrastructure requirements including 24/7 clinical availability, rapid response capabilities, and sophisticated remote monitoring present operational complexities. Additionally, equity concerns exist around which communities and populations can access these programs effectively.

Site-Neutral Payment: Addressing Cost Disparities

A less prominent but potentially significant provision moves toward site-neutral payments by requiring providers with off-campus outpatient departments to use separate identification numbers. This seemingly technical requirement addresses a substantial cost driver in American healthcare: the differential reimbursement rates for identical services depending on where they occur.

Currently, Medicare pays significantly more for certain procedures performed in hospital outpatient departments compared to independent physician offices, even when the service is identical and the facility is physically separate from the main hospital campus. This pricing differential creates financial incentives for hospitals to acquire physician practices and convert them to hospital outpatient departments, generating increased Medicare spending without corresponding improvements in care quality or patient outcomes.

The separate identification requirement creates infrastructure for more sophisticated payment differentiation. While the current legislation does not mandate immediate payment equalization, establishing distinct identifiers for off-campus departments enables future policy interventions that could align reimbursement more closely with actual resource costs rather than organizational affiliation.

This represents a gradual approach to addressing a politically sensitive issue. Hospital systems have vigorously defended existing payment structures, arguing that higher reimbursement reflects their standby capacity, regulatory compliance burdens, and safety-net obligations. Physician groups and policy analysts counter that payment should reflect resource intensity of specific services rather than organizational characteristics.

Medicaid DSH: Supporting Safety-Net Providers

The legislation delayed cuts to Medicaid disproportionate share hospital payments until fiscal year 2028, providing continued financial support to institutions serving high proportions of low-income and uninsured patients. These payments help offset the costs of uncompensated care and maintain access to services in vulnerable communities.

DSH payment reductions have been repeatedly delayed since their original authorization in the Affordable Care Act. The political difficulty of implementing these cuts reflects the fundamental tension between controlling healthcare spending and maintaining access to care for disadvantaged populations. Safety-net hospitals operate in challenging financial environments where patient populations generate limited revenue while presenting complex clinical needs.

By extending the delay through 2028, legislators provide breathing room for these institutions while postponing difficult allocation decisions. However, this pattern of repeated delays suggests that the original ACA framework for DSH reductions may be politically unsustainable, potentially requiring more comprehensive reform of how safety-net care is financed.

Broader Implications and Future Trajectory

This legislative package demonstrates how crisis moments create opportunities for substantive policy advancement. The government shutdown provided political cover for lawmakers to attach healthcare reforms that might have struggled to advance independently. By bundling PBM reform, telehealth extension, and hospital-at-home provisions with essential appropriations, legislators ensured these measures would receive minimal individual scrutiny while benefiting from the momentum to resolve the funding crisis.

The policy choices embedded in this legislation reflect evolving priorities in healthcare reform. Rather than pursuing comprehensive restructuring through major legislation like the Affordable Care Act, lawmakers are implementing targeted interventions addressing specific market failures and delivery inefficiencies. This incremental approach may be more politically sustainable but also risks creating patchwork solutions that fail to address systemic problems.

The pharmaceutical supply chain reforms illustrate this challenge. While PBM transparency requirements represent progress, they do not fundamentally address pharmaceutical pricing power, patent gaming strategies, or the absence of meaningful price negotiation in most Medicare drug coverage. Similarly, telehealth extensions expand access without resolving questions about appropriate utilization, quality standards, or long-term cost implications.

Looking forward, the extended timelines for telehealth and hospital-at-home programs create natural evaluation points. As the 2027 and 2030 deadlines approach, policymakers will face decisions about whether to make these provisions permanent, modify their scope, or allow them to sunset. The quality and comprehensiveness of data collection during these authorization periods will significantly influence these future choices.

The legislation also raises questions about the future of healthcare regulation under the Trump administration. The combination of deregulatory rhetoric with specific interventions in pharmaceutical markets suggests a complex approach that defies simple categorization. Further reforms targeting drug manufacturers, as suggested by PBM advocates, could emerge as political pressure for pharmaceutical cost control intensifies.

***

The healthcare provisions in this funding legislation represent significant policy developments with implications extending far beyond the immediate resolution of a government shutdown. PBM reforms attack long-standing opacity in pharmaceutical pricing, telehealth extensions acknowledge the permanence of pandemic-driven delivery innovations, and hospital-at-home authorization signals openness to reconceptualizing where acute care occurs.

These measures collectively reflect a healthcare system in transition, grappling with cost pressures, technological capabilities, and changing patient expectations. While none of these provisions represents revolutionary reform, their cumulative effect could substantially reshape healthcare delivery and financing over the coming years. The success of these initiatives will depend heavily on implementation details, stakeholder adaptation, and the quality of evidence generated during extended authorization periods.

As American healthcare continues evolving through incremental policy adjustments rather than comprehensive restructuring, the provisions in this legislation demonstrate both the possibilities and limitations of pragmatic reform. They address real problems without solving underlying systemic dysfunction, provide valuable flexibility while preserving fundamental market structures, and extend planning horizons while postponing ultimate decisions about permanent policy direction.

Sources

Healthcare Dive. (2026, February 4). Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions. Retrieved from https://www.healthcaredive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811020/